Climb Bio, Inc. Common Stock

CLYMNASDAQ • USD
ThemeBiotech - Drug Development›Immunology & Autoimmune
10.71 USD
↗ 0.03 (0.28%)AT CLOSE (03:59 PM EDT)
10.72
↗ 0.01 (0.09%)
POST MARKET (AS OF 07:30 PM EDT)
Post Market
AS OF 07:30 PM EDT
10.72
↗ 0.01 (0.09%)
🔴Market: CLOSED

Shares of Climb Bio, Inc. Common Stock (CLYM) are trading at $10.72. Our models show a "Sell" technical signal alongside a "Neutral" fundamental rating. Key drivers include a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bullish Golden Cross on the moving averages. On the valuation side, CLYM appears attractively valued relative to sector peers across key multiples.

Technical & fundamental data as of Oct 7, 2026.

Open?$10.43
High?$10.95
Low?$10.34
Prev. Close?$10.68
Volume?755.8K
Avg. Volume?1.7M
VWAP?$10.74
Rel. Volume?0.46x
Bid / Ask
Bid?$8.84 × 100
Ask?$12.29 × 100
Spread?$3.45
Midpoint?$10.57
Valuation & Ratios
Market Cap?613.4M
Shares Out?57.4M
Float?38.3M
Float %?66.7%
P/E Ratio?N/A
P/B Ratio?2.56
EPS?-$1.00
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Climb Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics for patients with immune-mediated diseases. Its pipeline includes Budoprutug, an anti-CD19 monoclonal antibody being developed for B-cell mediated diseases such as primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy.
Themes
Biotech - Drug Development›Immunology & AutoimmuneBiotech - Drug Development›Rare Disease Therapeutics
Employees
29
Market Cap
613.4M
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.climbbio.com
Listed
2021-08-10
Address
20 WILLIAM STREET
WELLESLEY HILLS, MA 02481
Phone: 1-866-857-2596
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+1/3)
Medium-Term (Wave)?▼ Bearish(-3/3)
Short-Term (Ripple)?– Neutral(0/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
100
Momentum?
50
Short Sent.?
21
Piotroski F-Score?0/9Weak
Altman Z-Score?52.76Safe
Confidence?41%Low
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?22.23%Squeeze Risk
Short Interest?8.5M
Days to Cover?4.5
Free Float38.3M
Avg Daily Volume1.9M
Settlement Date2026-09-15
Financial Health
Current Ratio?31.45Strong
Quick Ratio?31.45Strong
Cash Ratio?7.43Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
100/100
P/E?
N/A▾
P/B?
Peers
100
S&P
63
2.56CHEAP▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-8.8CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
7
-24.1%WEAK▾
ROA?
S&P
3
-23.4%WEAK▾
Cash Flow & Enterprise
FCF?$-53068000
Enterprise Value?$569.3M
Fundamentals ratios updated end of day
MarketsMoversWatchlist